Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion type Assertion NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_head.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion description "[Of the 31 patients in remission at 12 months post-HCT, disease-free survival was 86% in patients with MRD <10(-4) and 20% in those with MRD ?10(-4) (relapse hazard ratio (HR) 9.0; 95% confidence interval (CI) 2.5-32; P<0.0001), with median follow-up of 36 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_provenance.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion evidence source_evidence_literature NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_provenance.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion SIO_000772 23419792 NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_provenance.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion wasDerivedFrom befree-20140225 NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_provenance.
- NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_assertion wasGeneratedBy ECO_0000203 NP843089.RAxu199QWug3J69YqxBvmK5kSvZej6CFdUNk5ZGbFALDc130_provenance.